Compare Alcon AG (ALC) vs Figs Inc (FIGS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Figs Inc — how do they compare? Alcon AG trades at $66.79 (market cap $32.69B), while Figs Inc trades at $10.16 (market cap $1.65B). The key difference: Alcon AG is far larger — about 19.8× Figs Inc's market cap, and Alcon AG pays a 0.54% dividend while Figs Inc pays none. Which is the better fit depends on your goals.
| ALC | FIGS | |
|---|---|---|
Market Cap | $32.69B | $1.65B |
Sector | Health | Consumer Cyclical |
52-Week High | $92.22 | $17.12 |
52-Week Low | $62.02 | $5.81 |
Enterprise Value | $36.28B | $1.44B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
FIGS stock trades at $9.90, down 0.9% today, with a mixed technical picture showing a bearish moving average trend but oversold RSI levels. The company reported strong Q1 2026 earnings, beating estimates with 28% revenue growth and raised full-year guidance. Analyst consensus is a Buy with a $18.00 price target, implying significant upside, though valuation ratios like a P/E of 44.91 remain elevated.
The outlook is cautiously optimistic, driven by robust revenue growth, expanding margins, and global expansion. Key risks include cost pressures from tariffs and freight, competitive threats, and the stock's high valuation requiring sustained execution. Near-term performance hinges on Q2 2026 earnings delivery against a $0.07 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →
